NCT00863980

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,500 (actual)
• Sponsor: Kyoto Prefectural University of Medicine · Academic / Other
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study is aimed to investigate whether treatment with Telmisartan is more effective than Candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease.

Detailed description

This study is aimed to investigate whether treatment with Telmisartan is more effective than Candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease. Study design: PROBE(Prospective, Randomized, Open-labeled Blind Endpoints)

Conditions

• Acute Myocardial Infarction
• Angina Pectoris
• Myocardial Ischemia
• Acute Coronary Syndrome
• Hypertension

Interventions

Type	Name	Description
DRUG	Micardis (Telmisartan)	40-80 mg/day oral administration
DRUG	Blopress (Candesartan)	8-12 mg/day oral administration

Timeline

• Start date: 2009-04-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2009-03-18
• Last updated: 2015-09-03

Locations

32 sites across 1 country: Japan